Sort by
Items per page

Send to

Choose Destination

Best matches for GLYCOPYRRONIUM/TU:

Search results

Items: 1 to 20 of 277


Pharmacology, toxicology and clinical safety of glycopyrrolate.

Chabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C.

Toxicol Appl Pharmacol. 2019 May 1;370:154-169. doi: 10.1016/j.taap.2019.03.016. Epub 2019 Mar 21. Review.


Qbrexza - A glycopyrronium cloth for axillary hyperhidrosis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jan 28;61(1564):10-11. Review. No abstract available.


Topical Treatment of Primary Focal Hyperhidrosis, Part 1.

Zur E.

Int J Pharm Compd. 2019 Jan-Feb;23(1):23-31.


Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.

Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, Shen S, Goyal P, Mezzi K, Kostikas K.

Respir Res. 2019 Jan 8;20(1):4. doi: 10.1186/s12931-019-0972-7.


Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.

Skoupa J, Kasak V, Klimes J, Valena T.

Value Health Reg Issues. 2018 Sep;16:112-118. doi: 10.1016/j.vhri.2018.09.002. Epub 2018 Oct 27.


Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.

Kupczyk M, Kuna P.

Expert Rev Respir Med. 2019 Jan;13(1):5-11. doi: 10.1080/17476348.2019.1548937. Epub 2018 Nov 27.


Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.

Hebert AA, Glaser DA, Green L, Werschler WP, Forsha DW, Drew J, Gopalan R, Pariser DM.

Pediatr Dermatol. 2019 Jan;36(1):89-99. doi: 10.1111/pde.13723. Epub 2018 Nov 19. Erratum in: Pediatr Dermatol. 2019 May;36(3):424.


A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.

De Backer W, De Backer J, Vos W, Verlinden I, Van Holsbeke C, Clukers J, Hajian B, Siddiqui S, Jenkins M, Reisner C, Martin UJ.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 30;13:2673-2684. doi: 10.2147/COPD.S171707. eCollection 2018.


[Trimbow® : twice-daily triple combination for the treatment of COPD].

Corhay JL, Bonhomme O, Guiot J.

Rev Med Liege. 2018 Sep;73(9):480-484. French.


Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide.

Mantero M, Radovanovic D, Santus P, Blasi F.

Int J Chron Obstruct Pulmon Dis. 2018 Jul 30;13:2319-2333. doi: 10.2147/COPD.S147484. eCollection 2018. Review.


Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.

Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, Drew J, Quiring J, Pariser DM.

J Am Acad Dermatol. 2019 Jan;80(1):128-138.e2. doi: 10.1016/j.jaad.2018.07.002. Epub 2018 Jul 10.


Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.

Singh D.

Expert Opin Pharmacother. 2018 Aug;19(11):1279-1287. doi: 10.1080/14656566.2018.1498841. Epub 2018 Aug 13.


Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.

Tashkin DP, Gross NJ.

Int J Chron Obstruct Pulmon Dis. 2018 Jun 12;13:1873-1888. doi: 10.2147/COPD.S162646. eCollection 2018. Review.


Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

Anzueto AR, Kostikas K, Mezzi K, Shen S, Larbig M, Patalano F, Fogel R, Banerji D, Wedzicha JA.

Respir Res. 2018 Jun 20;19(1):121. doi: 10.1186/s12931-018-0830-z.


Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).

Beeh KM, Emirova A, Prunier H, Santoro D, Nandeuil MA.

Int J Chron Obstruct Pulmon Dis. 2018 May 25;13:1701-1711. doi: 10.2147/COPD.S168493. eCollection 2018.


Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial.

Kerwin E, Wachtel A, Sher L, Nyberg J, Darken P, Siddiqui S, Duncan EA, Reisner C, Dorinsky P.

Respir Med. 2018 Jun;139:39-47. doi: 10.1016/j.rmed.2018.04.013. Epub 2018 Apr 19.


Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent.

Dorinsky P, DePetrillo P, Siddiqui S, Maes A, Reisner C.

Pulm Pharmacol Ther. 2018 Aug;51:18-25. doi: 10.1016/j.pupt.2018.05.001. Epub 2018 May 12.


Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease.

Fakih F, Spangenthal S, Sigal B, Darken P, Maes A, Siddiqui S, Gillen M, Reisner C, Martin UJ.

Respir Med. 2018 May;138:74-80. doi: 10.1016/j.rmed.2018.03.033. Epub 2018 Mar 30.


Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

Supplemental Content

Loading ...
Support Center